Profusa Inc stock drops significantly amid market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Should l Buy PFSA?
Source: Benzinga
Profusa Inc's stock price fell by 12.14% as it crossed below the 20-day SMA, indicating a significant downward movement in its value.
The decline in Profusa's stock price is attributed to sector rotation, as the broader market showed mixed signals with the Nasdaq-100 slightly up while the S&P 500 experienced a minor decline. This divergence in market performance often leads to shifts in investor focus, impacting stocks like Profusa negatively despite the overall market conditions.
Investors may need to reassess their positions in Profusa Inc, especially in light of the current market dynamics that suggest a cautious approach towards stocks in this sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFSA
About PFSA
Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Profusa Acquires PanOmics for $30 Million to Expand Molecular Diagnostics
- Acquisition Announcement: Profusa, Inc. has signed a Letter of Intent to acquire the multi-omics diagnostics platform PanOmics from BioInsights LLC for $30 million, strategically expanding its molecular diagnostics business, which is expected to significantly enhance the company's market position in biosensing, diagnostics, and precision medicine.
- Stock Surge: Following the acquisition news, Profusa's stock soared by 122.96%, increasing by $1.69, indicating strong market optimism regarding the deal and reflecting investor confidence in the company's future growth potential.
- Transaction Details: Under the terms of the agreement, Profusa will pay $30 million in equity securities to gain exclusive rights to the PanOmics platform, while BioInsights will provide a specified number of samples for validation and receive a 3% royalty on net revenue, further enhancing the commercial value of the transaction.
- Strategic Growth Outlook: Profusa's CEO Ben Hwang stated that this acquisition will establish a foundation for entering the pancreatic cancer market, supporting the development of multiple indications, which signals the company's strategic positioning for long-term growth, particularly in the context of its Lumee Oxygen Platform for monitoring peripheral artery disease and chronic wounds.
See More
Profusa Shares Soar 80% on PanOmics Acquisition Announcement
- Stock Surge: Profusa, Inc. (PFSA) shares surged over 80% in pre-market trading on Monday, reflecting strong market enthusiasm for its acquisition of the PanOmics diagnostic platform, indicating investor confidence in the company's growth potential.
- Acquisition Plan: Profusa plans to acquire BioInsights' PanOmics platform and related expertise for approximately $30 million, gaining exclusive rights that will significantly enhance its competitiveness in the molecular diagnostics space.
- Equity Payment Structure: The consideration for the deal will be paid in equity, with BioInsights receiving a 3% royalty on future net revenue, a structure that not only alleviates Profusa's cash flow pressure but may also enhance its long-term financial performance.
- Technology Integration Outlook: Through this acquisition, Profusa expects to integrate its real-time biochemistry monitoring technology with the PanOmics platform, driving product innovation and market expansion while further solidifying its position in the biotechnology sector.
See More
Profusa Acquires Multi-Omics Diagnostics Platform to Enhance Cancer Monitoring
- Strategic Expansion: Profusa has announced a Letter of Intent to acquire BioInsights' PanOmics™ multi-omics diagnostics platform, which is expected to add $30 million in shareholder equity, further solidifying its position at the intersection of biosensing, diagnostics, and precision medicine.
- Clinical Collaboration: The partnership with Mayo Clinic will provide Profusa with access to clinical samples and a clear validation pathway, enabling accelerated development and clinical adoption, thereby unlocking significant near-term commercial value in pancreatic cancer monitoring.
- Market Opportunity: With over 13,000 pancreatic resections performed annually in the U.S., representing a $26 million annual revenue opportunity, Profusa's integrated platform aims to develop multi-indication diagnostic assays and real-time physiological monitoring solutions to meet market demands.
- Capital Efficiency: By gaining access to clinically annotated samples and established assay design infrastructure, Profusa is set to create a defined pathway from development to revenue generation, which is expected to drive its expansion into multiple high-growth markets.
See More
Profusa Acquires PanOmics Platform to Advance Precision Diagnostics
- Strategic Expansion: Profusa has signed a Letter of Intent to acquire BioInsights' PanOmics™ multi-omics diagnostics platform, which is expected to establish a foundation for scalable multi-product diagnostics and monitoring in the fields of biosensing, diagnostics, and precision medicine.
- Partnership Development: The collaboration with Mayo Clinic will provide Profusa with access to clinical samples and a clear validation pathway, enabling the company to accelerate development and drive clinical adoption, thereby unlocking significant near-term commercial value in pancreatic cancer applications.
- Financial Impact: This transaction will add $30 million in shareholder equity to Profusa's balance sheet, and it is anticipated to create a capital-efficient pathway from development to revenue generation, enhancing the company's financial stability.
- Market Opportunity: With over 13,000 pancreatic cancer resections performed annually in the U.S., representing a $26 million annual revenue opportunity, the integration of Profusa's technologies is poised to establish a sustainable revenue stream in this high-growth market.
See More
Profusa Cancels $15 Million Offering Amid Revenue Reevaluation
- Offering Cancellation: Profusa has decided against proceeding with a $15 million public offering, reflecting a reassessment of its projected revenue for 2026, indicating a potential weakening in its short-term liquidity needs in the current market environment.
- Focus on Smaller Offering: The company intends to pursue a smaller, more targeted offering to support projected revenue from its LumeeTMOxygen product launch in Europe in Q2 2026 and to accelerate its collaboration with Mayo Clinic, signaling a strategic shift towards addressing specific market demands.
- Market Launch Progress: Profusa anticipates launching its products in the European oxygen market in Q2 2026 and plans to enter the U.S. market in late 2026 in collaboration with Mayo Clinic, demonstrating proactive advancements in product development and market outreach.
- Operational and Financial Optimization: Chairman and CEO Ben Hwang stated that the decision to cancel the larger offering aligns better with current operational requirements, emphasizing significant progress in strengthening the company's balance sheet and commercial operations, which may lay a foundation for future market performance.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Profusa Acquires PanOmics for $30 Million to Expand Molecular Diagnostics
- Acquisition Announcement: Profusa, Inc. has signed a Letter of Intent to acquire the multi-omics diagnostics platform PanOmics from BioInsights LLC for $30 million, strategically expanding its molecular diagnostics business, which is expected to significantly enhance the company's market position in biosensing, diagnostics, and precision medicine.
- Stock Surge: Following the acquisition news, Profusa's stock soared by 122.96%, increasing by $1.69, indicating strong market optimism regarding the deal and reflecting investor confidence in the company's future growth potential.
- Transaction Details: Under the terms of the agreement, Profusa will pay $30 million in equity securities to gain exclusive rights to the PanOmics platform, while BioInsights will provide a specified number of samples for validation and receive a 3% royalty on net revenue, further enhancing the commercial value of the transaction.
- Strategic Growth Outlook: Profusa's CEO Ben Hwang stated that this acquisition will establish a foundation for entering the pancreatic cancer market, supporting the development of multiple indications, which signals the company's strategic positioning for long-term growth, particularly in the context of its Lumee Oxygen Platform for monitoring peripheral artery disease and chronic wounds.
See More
Profusa Shares Soar 80% on PanOmics Acquisition Announcement
- Stock Surge: Profusa, Inc. (PFSA) shares surged over 80% in pre-market trading on Monday, reflecting strong market enthusiasm for its acquisition of the PanOmics diagnostic platform, indicating investor confidence in the company's growth potential.
- Acquisition Plan: Profusa plans to acquire BioInsights' PanOmics platform and related expertise for approximately $30 million, gaining exclusive rights that will significantly enhance its competitiveness in the molecular diagnostics space.
- Equity Payment Structure: The consideration for the deal will be paid in equity, with BioInsights receiving a 3% royalty on future net revenue, a structure that not only alleviates Profusa's cash flow pressure but may also enhance its long-term financial performance.
- Technology Integration Outlook: Through this acquisition, Profusa expects to integrate its real-time biochemistry monitoring technology with the PanOmics platform, driving product innovation and market expansion while further solidifying its position in the biotechnology sector.
See More
Profusa Acquires Multi-Omics Diagnostics Platform to Enhance Cancer Monitoring
- Strategic Expansion: Profusa has announced a Letter of Intent to acquire BioInsights' PanOmics™ multi-omics diagnostics platform, which is expected to add $30 million in shareholder equity, further solidifying its position at the intersection of biosensing, diagnostics, and precision medicine.
- Clinical Collaboration: The partnership with Mayo Clinic will provide Profusa with access to clinical samples and a clear validation pathway, enabling accelerated development and clinical adoption, thereby unlocking significant near-term commercial value in pancreatic cancer monitoring.
- Market Opportunity: With over 13,000 pancreatic resections performed annually in the U.S., representing a $26 million annual revenue opportunity, Profusa's integrated platform aims to develop multi-indication diagnostic assays and real-time physiological monitoring solutions to meet market demands.
- Capital Efficiency: By gaining access to clinically annotated samples and established assay design infrastructure, Profusa is set to create a defined pathway from development to revenue generation, which is expected to drive its expansion into multiple high-growth markets.
See More
Profusa Acquires PanOmics Platform to Advance Precision Diagnostics
- Strategic Expansion: Profusa has signed a Letter of Intent to acquire BioInsights' PanOmics™ multi-omics diagnostics platform, which is expected to establish a foundation for scalable multi-product diagnostics and monitoring in the fields of biosensing, diagnostics, and precision medicine.
- Partnership Development: The collaboration with Mayo Clinic will provide Profusa with access to clinical samples and a clear validation pathway, enabling the company to accelerate development and drive clinical adoption, thereby unlocking significant near-term commercial value in pancreatic cancer applications.
- Financial Impact: This transaction will add $30 million in shareholder equity to Profusa's balance sheet, and it is anticipated to create a capital-efficient pathway from development to revenue generation, enhancing the company's financial stability.
- Market Opportunity: With over 13,000 pancreatic cancer resections performed annually in the U.S., representing a $26 million annual revenue opportunity, the integration of Profusa's technologies is poised to establish a sustainable revenue stream in this high-growth market.
See More
Profusa Cancels $15 Million Offering Amid Revenue Reevaluation
- Offering Cancellation: Profusa has decided against proceeding with a $15 million public offering, reflecting a reassessment of its projected revenue for 2026, indicating a potential weakening in its short-term liquidity needs in the current market environment.
- Focus on Smaller Offering: The company intends to pursue a smaller, more targeted offering to support projected revenue from its LumeeTMOxygen product launch in Europe in Q2 2026 and to accelerate its collaboration with Mayo Clinic, signaling a strategic shift towards addressing specific market demands.
- Market Launch Progress: Profusa anticipates launching its products in the European oxygen market in Q2 2026 and plans to enter the U.S. market in late 2026 in collaboration with Mayo Clinic, demonstrating proactive advancements in product development and market outreach.
- Operational and Financial Optimization: Chairman and CEO Ben Hwang stated that the decision to cancel the larger offering aligns better with current operational requirements, emphasizing significant progress in strengthening the company's balance sheet and commercial operations, which may lay a foundation for future market performance.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
